Pancreatic Cancer Research

ResearcherWakayama Medical UniversityActive in the last 2 years

Reiko Ashida

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-6918-3066; OpenAlex author ID A5085373987. Sources: OpenAlex.

Their work

Papers
35 (first author 6, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
113
Papers, trials and grants by year

2013: 1 paper · 2014: 1 paper · 2015: 1 paper · 2016: none · 2017: 1 paper · 2018: 1 paper · 2019: none · 2020: 4 papers · 2021: 7 papers · 2022: 5 papers · 2023: 2 papers · 2024: 2 papers · 2025: 4 papers · 2026: 6 papers

Papers 35

  1. Comparison of Nanoliposomal Irinotecan Plus Fluorouracil/Leucovorin and S-1, Irinotecan, and Oxaliplatin as Second-Line Chemotherapy After Gemcitabine Plus Nab… First author DOI 10.1002/jhbp.70122↗
  2. Reply to "Prognostic value of functional assessment in sarcopenia among pancreatic cancer patients". Co-author DOI 10.1007/s00535-026-02446-w↗
  3. Contrast-enhanced harmonic endoscopic ultrasonography (EUS)-guided tissue acquisition significantly improves diagnostic yield for small liver metastases derive… Co-author DOI 10.1016/j.pan.2025.12.001↗
  4. Endoscopic ultrasound-guided fiducial marker placement for image-guided proton beam therapy in pancreatic cancer: implications for positional accuracy and posi… Co-author DOI 10.1093/jrr/rrag082↗
  5. Comparative Study of Pathological and Imaging Findings in High-Grade Pancreatic Intraepithelial Neoplasia: A Multicenter Analysis by the Japan Study Group on E… Co-author DOI 10.1097/mpa.0000000000002710↗
  6. KRAS Mutations in Duodenal Lavage Fluid After Secretin Stimulation for Detection of Pancreatic Cancer. Co-author DOI 10.1097/sla.0000000000006645↗
  7. Efficacy of liposomal irinotecan + 5-FU/LV vs. S-1 in gemcitabine-refractory metastatic pancreatic cancer: a real-world study using inverse probability of trea… Co-author DOI 10.1007/s00535-024-02186-9↗
  8. Correction: Efficacy of liposomal irinotecan + 5-FU/LV vs. S-1 in gemcitabine-refractory metastatic pancreatic cancer: a real-world study using inverse probabi… Co-author DOI 10.1007/s00535-025-02215-1↗
  9. Impact of sarcopenia and changes in skeletal muscle mass on prognosis of patients with pancreatic ductal adenocarcinoma receiving chemotherapy with first-line … Co-author DOI 10.1007/s00535-025-02283-3↗
  10. The effect of neoadjuvant chemoradiation therapy in resectable pancreatic cancer was independent of intratumoral vascularization. First author DOI 10.1186/s12876-025-04108-2↗
  11. K-ras gene mutation analysis to diagnosis pancreatic adenocarcinoma from endoscopic ultrasound-guided tissue acquisition; a systematic review and meta-analysis. First author DOI 10.1016/j.pan.2023.11.012↗
  12. Insight from Lymphocyte-Albumin Scores into Treatment Continuity of Nanoliposomal Irinotecan With 5-Fluorouracil and L-leucovorin in Metastatic Pancreatic Canc… Co-author DOI 10.21873/invivo.13768↗
  13. Clinical Practice Guidelines for Pancreatic Cancer 2022 from the Japan Pancreas Society: a synopsis. Co-author DOI 10.1007/s10147-023-02317-x↗
  14. Utility of contrast-enhanced harmonic endoscopic ultrasonography for prediction of pathological response after neoadjuvant chemotherapy in patients with pancre… First author DOI 10.1016/j.pan.2023.10.016↗
  15. Impact of sarcopenia on prediction of progression-free survival and overall survival of patients with pancreatic ductal adenocarcinoma receiving first-line gem… Co-author DOI 10.1016/j.pan.2021.12.013↗
  16. Contrast-enhanced harmonic endoscopic ultrasonography for predicting the efficacy of first-line gemcitabine and nab-paclitaxel chemotherapy in pancreatic cance… First author DOI 10.1016/j.pan.2022.04.005↗
  17. Endoscopic ultrasound-guided tissue acquisition for pancreatic ductal adenocarcinoma in the era of precision medicine. Co-author DOI 10.1111/den.14344↗
  18. New Screening System Using Forward-Viewing Radial Endoscopic Ultrasound and Magnetic Resonance Imaging for High-Risk Individuals With Familial History of Pancr… Co-author DOI 10.3389/fmed.2022.928182↗
  19. Kras Gene Analysis Using Liquid-Based Cytology Specimens Predicts Therapeutic Responses and Prognosis in Patients with Pancreatic Cancer. First author DOI 10.3390/cancers14030551↗
  20. Efficacy and safety of modified fluorouracil/leucovorin plus irinotecan and oxaliplatin (mFOLFIRINOX) compared with S-1 as second-line chemotherapy in metastat… Co-author DOI 10.1002/jgh3.12555↗
  21. Computed tomography findings for predicting the future occurrence of pancreatic cancer: value of pancreatic volumetry. Co-author DOI 10.1007/s10147-021-01915-x↗
  22. Value of Low-Mechanical-Index Contrast-Enhanced Transabdominal Ultrasound for Diagnosis of Pancreatic Cancer: A Meta-analysis. Co-author DOI 10.1016/j.ultrasmedbio.2021.08.005↗
  23. Covered self-expandable metal stents versus plastic stents for preoperative biliary drainage in patient receiving neo-adjuvant chemotherapy for borderline rese… Co-author DOI 10.1111/den.13926↗
  24. Value of contrast-enhanced harmonic endoscopic ultrasound for diagnosing hepatic metastases of pancreatic cancer: A prospective study. Co-author DOI 10.1111/jgh.15661↗
  25. Predictive Factors for Pancreatic Cancer and Its Early Detection Using Special Pancreatic Ultrasonography in High-Risk Individuals. Co-author DOI 10.3390/cancers13030502↗
  26. The Survival Benefit of Chemoradiotherapy following Induction Chemotherapy with Gemcitabine Plus Nab-Paclitaxel for Unresectable Locally Advanced Pancreatic Ca… Co-author DOI 10.3390/cancers13184733↗
  27. Effectiveness of Contrast-Enhanced Ultrasonography for the Characterization of Small and Early Stage Pancreatic Adenocarcinoma. Co-author DOI 10.1016/j.ultrasmedbio.2020.04.016↗
  28. Efficacy of Larger-Diameter Plastic Stent Placement for Preoperative Biliary Drainage in Patients Receiving Neoadjuvant Chemoradiation for Pancreatic Cancer. Co-author DOI 10.1097/mpa.0000000000001509↗
  29. Clinical Utility of Pancreatic Cancer Circulating Tumor DNA in Predicting Disease Progression, Prognosis, and Response to Chemotherapy. Co-author DOI 10.1097/mpa.0000000000001652↗
  30. Endoscopic ultrasound-guided fiducial marker placement for neoadjuvant chemoradiation therapy for resectable pancreatic cancer. Co-author DOI 10.4251/wjgo.v12.i7.768↗
  31. The Role of Transabdominal Ultrasound in the Diagnosis of Early Stage Pancreatic Cancer: Review and Single-Center Experience. Co-author DOI 10.3390/diagnostics9010002↗
  32. Familial pancreatic cancer: Concept, management and issues. Co-author DOI 10.3748/wjg.v23.i6.935↗
  33. [The progress of chemotherapy for advanced pancreatic cancer]. Co-author DOI 10.11405/nisshoshi.112.2119↗
  34. Duodenal Hemorrhage from Pancreatic Cancer Infiltration Controlled through Combination Therapy with Gemcitabine and S-1. Co-author DOI 10.1159/000364819↗
  35. Safety and effectiveness of gemcitabine in 855 patients with pancreatic cancer under Japanese clinical practice based on post-marketing surveillance in Japan. Co-author DOI 10.1093/jjco/hys211↗

Closest collaborators

The 25 strongest of 113 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Masayuki Kitano · 17 shared papers, 2017–2026 · strength 3.22
  2. Takashi Tamura · 12 shared papers, 2021–2026 · strength 2.29
  3. Yasunobu Yamashita · 12 shared papers, 2021–2026 · strength 2.14
  4. Yuki Kawaji · 11 shared papers, 2021–2026 · strength 2.01
  5. Masahiro Itonaga · 11 shared papers, 2021–2026 · strength 2.01
  6. Tomoya Emori · 9 shared papers, 2021–2026 · strength 1.56
  7. Kazuyoshi Ohkawa · 10 shared papers, 2020–2026 · strength 1.35
  8. Kenji Ikezawa · 9 shared papers, 2020–2026 · strength 1.24
  9. Manabu Kawai · 8 shared papers, 2021–2024 · strength 1.15
  10. Ryoji Takada · 9 shared papers, 2014–2025 · strength 1.08
  11. Keiichi Hatamaru · 7 shared papers, 2021–2023 · strength 0.91
  12. Hidenori Takahashi · 7 shared papers, 2015–2025 · strength 0.89
  13. Nobuyasu Fukutake · 8 shared papers, 2014–2022 · strength 0.84
  14. Kazuhiro Katayama · 7 shared papers, 2018–2021 · strength 0.72
  15. Tatsuya Ioka · 8 shared papers, 2013–2022 · strength 0.71
  16. Shigenori Nagata · 4 shared papers, 2020–2025 · strength 0.62
  17. Chigusa Morizane · 4 shared papers, 2017–2026 · strength 0.57
  18. Teruki Teshima · 4 shared papers, 2015–2025 · strength 0.51
  19. Keiji Hanada · 3 shared papers, 2017–2026 · strength 0.47
  20. Takuo Yamai · 5 shared papers, 2014–2021 · strength 0.46
  21. Hirofumi Akita · 3 shared papers, 2020–2025 · strength 0.45
  22. Akinori Shimizu · 2 shared papers, 2026 · strength 0.43
  23. Takeshi Terashima · 3 shared papers, 2017–2025 · strength 0.37
  24. Junji Furuse · 3 shared papers, 2017–2025 · strength 0.37
  25. Makoto Ueno · 3 shared papers, 2017–2025 · strength 0.37

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.